These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 2552711)
1. [Isolation of hemolytic cultures of Bordetella pertussis intended for the production of acellular pertussis preparations and the characterization of their biological properties]. Miriasova LV; Vasnak'ian IA; Kopaeva TV; Remova TN; Kozhevnikova EV Zh Mikrobiol Epidemiol Immunobiol; 1989 Jun; (6):15-8. PubMed ID: 2552711 [TBL] [Abstract][Full Text] [Related]
2. [A polyvalent complex of Bordetella pertussis antigens as the basis for an acellular pertussis vaccine]. Zakharova NS; Shmeleva EI; Remova TN; Bazhanova IG; Ozeretskovskaia MN; Mertsalova NU; Britsina MV; Ermolova EV; Zaĭtsev EM Zh Mikrobiol Epidemiol Immunobiol; 1997; (3):70-2. PubMed ID: 9304336 [TBL] [Abstract][Full Text] [Related]
3. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques. Gupta RK; Saxena SN; Sharma SB; Ahuja S Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314 [TBL] [Abstract][Full Text] [Related]
4. [An acellular pertussis vaccine based on the natural complex of antigens isolated from the supernatant of a synthetic culture medium]. Zakharova NS; Remova TN; Bazhanova IG; Ozeretskovskaia MH; Britsina MV; Shmeleva EI; Mertsalova NU; Ermolova EI; Sukhinova EE; Bulk VF; Sirotinskiĭ AV; Poluiianova AG; Sviridov VV; Vartanian IuP Zh Mikrobiol Epidemiol Immunobiol; 1997; (3):67-70. PubMed ID: 9304334 [TBL] [Abstract][Full Text] [Related]
5. [The expression of Bordetella pertussis protective antigens during bacterial multiplication on a medium with a fixed chemical composition]. Shmeleva EI; Mertsalova NU; Sukhinova EV; Kirillova GA; Remova TN; Bazhanova IG; Ozeretskovskaia MN; Britsina MV; Ermolova EV; Zakharova NS Zh Mikrobiol Epidemiol Immunobiol; 1997; (2):47-50. PubMed ID: 9245141 [TBL] [Abstract][Full Text] [Related]
6. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines. Hegerle N; Guiso N Expert Rev Vaccines; 2014 Sep; 13(9):1135-46. PubMed ID: 24953157 [TBL] [Abstract][Full Text] [Related]
7. Bordetella pertussis vaccine strains and circulating isolates in Serbia. Dakic G; Kallonen T; Elomaa A; Pljesa T; Vignjevic-Krastavcevic M; He Q Vaccine; 2010 Feb; 28(5):1188-92. PubMed ID: 19945417 [TBL] [Abstract][Full Text] [Related]
8. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers. Sato Y; Sato H Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530 [TBL] [Abstract][Full Text] [Related]
9. Human T-cell immunity against Bordetella pertussis analyzed at clonal level. Tagliabue A; De Magistris MT; Rappuoli R Tokai J Exp Clin Med; 1988; 13 Suppl():253-7. PubMed ID: 2908527 [TBL] [Abstract][Full Text] [Related]
10. The purification and characterization of an acellular pertussis vaccine. Chazono M; Yoshida I; Konobe T; Fukai K J Biol Stand; 1988 Apr; 16(2):83-9. PubMed ID: 2897370 [TBL] [Abstract][Full Text] [Related]
11. Bordetella pertussis population dynamics and phylogeny in Japan after adoption of acellular pertussis vaccines. Zomer A; Otsuka N; Hiramatsu Y; Kamachi K; Nishimura N; Ozaki T; Poolman J; Geurtsen J Microb Genom; 2018 May; 4(5):. PubMed ID: 29771235 [TBL] [Abstract][Full Text] [Related]
12. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance. Dorji D; Mooi F; Yantorno O; Deora R; Graham RM; Mukkur TK Med Microbiol Immunol; 2018 Feb; 207(1):3-26. PubMed ID: 29164393 [TBL] [Abstract][Full Text] [Related]
13. Outer membrane vesicles derived from Bordetella parapertussis as an acellular vaccine against Bordetella parapertussis and Bordetella pertussis infection. Bottero D; Gaillard ME; Errea A; Moreno G; Zurita E; Pianciola L; Rumbo M; Hozbor D Vaccine; 2013 Oct; 31(45):5262-8. PubMed ID: 24012570 [TBL] [Abstract][Full Text] [Related]
14. The role of B. pertussis vaccine antigen gene variants in pertussis resurgence and possible consequences for vaccine development. Preston A Hum Vaccin Immunother; 2016 May; 12(5):1274-6. PubMed ID: 26889694 [TBL] [Abstract][Full Text] [Related]
15. Analysis of Bordetella pertussis isolates collected in Japan before and after introduction of acellular pertussis vaccines. Guiso N; Boursaux-Eude C; Weber C; Hausman SZ; Sato H; Iwaki M; Kamachi K; Konda T; Burns DL Vaccine; 2001 Apr; 19(23-24):3248-52. PubMed ID: 11312021 [TBL] [Abstract][Full Text] [Related]
16. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. Bottero D; Gaillard ME; Fingermann M; Weltman G; Fernández J; Sisti F; Graieb A; Roberts R; Rico O; Ríos G; Regueira M; Binsztein N; Hozbor D Clin Vaccine Immunol; 2007 Nov; 14(11):1490-8. PubMed ID: 17699837 [TBL] [Abstract][Full Text] [Related]
17. Prospects for a new acellular pertussis vaccine. Manclark CR; Burns DL Ann Inst Pasteur Microbiol (1985); 1985; 136B(3):323-9. PubMed ID: 2870676 [TBL] [Abstract][Full Text] [Related]
18. Genetic and antigenic analysis of Bordetella pertussis isolates recovered from clinical cases in Ontario, Canada, before and after the introduction of the acellular pertussis vaccine. Tsang RS; Sill ML; Martin IE; Jamieson F Can J Microbiol; 2005 Oct; 51(10):887-92. PubMed ID: 16333349 [TBL] [Abstract][Full Text] [Related]
19. Engineering bacterial toxin for the development of new vaccine against pertussis. Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870 [TBL] [Abstract][Full Text] [Related]